Close Menu

Miragen

Though not as advanced a therapeutic technology as its RNAi cousin, microRNA received a lot of positive attention from the investment community in 2012, with the top companies in the space pulling in nearly $150 million in financing dollars over the past year.

Mirna Therapeutics this week announced that it has closed a Series C round of financing, raising $34.5 million in what is the microRNA therapeutics field's biggest single round of private investment.

Miragen Therapeutics this week announced that it has closed a $20 million Series B round of financing.

Silence Therapeutics announced this week that it has signed a deal under which Miragen will evaluate its microRNA therapeutic candidates in combination with Silence's cationic lipid-based DBTC delivery technology.

Miragen Therapeutics this week announced the publication of preclinical data showing that a specific microRNA, miR-15, is up-regulated in response to ischemic damage in two model systems.

RxGen and Miragen Therapeutics said this week that they have received a grant from the National Institutes of Health to continue preclinical research on microRNA targeting in cardiovascular disease.

Pages

According to New Scientist, GEDmatch changed its terms and conditions over the weekend to opt its users out of law enforcement searches.

The Atlantic looks into time spent pursuing gene leads generated through candidate gene studies.

A twin study uncovers evidence that genes may influence whether someone gets a dog, Martha Stewart reports.

In PNAS this week: Cdx2 cells can help regenerate heart tissue in mice following a heart attack, PIWI-interacting small RNA levels in human cancer, and more.